Long-term Effectiveness of Mailed Nicotine Replacement Therapy: A 5-year Follow-up

Smoking Cessation Clinical Trial

Official title:

Long-term Effectiveness of Mailed Nicotine Replacement Therapy: A 5-year Follow-up

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03097445
• Other study ID #: 216-2005
• Status: Completed
• Phase: N/A
• Start date: June 4, 2017
• Est. completion date: August 22, 2019

Study information

• Verified date: January 2020
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will perform a 5-year follow-up survey of participants in a randomized controlled trial that evaluated the effectiveness of providing 5 weeks of free NRT (in the form of the nicotine patch) by expedited postal mail without behavioural assistance to regular adult smokers recruited across Canada interested in receiving it (clinicaltrials.gov Identifier: NCT01429129).

Description:

Our group recently completed a randomized controlled trial evaluating the efficacy of providing 5 weeks of free NRT (in the form of the nicotine patch) by expedited postal mail without behavioural assistance to regular adult smokers recruited across Canada interested in receiving it (clinicaltrials.gov Identifier: NCT01429129). The findings revealed that the provision of free nicotine patches via mail resulted in more than a doubling of 30-day abstinence quit rates at a six-month follow-up compared to the no intervention control group (7.6% versus 3.0%; odds ratio of 2.65). While this trial provided evidence for the effectiveness of nicotine patches as a tobacco cessation aid in real world settings, the findings speak only to the short-term effectiveness of NRT. As evidence for NRT effectiveness has been largely restricted to a final follow-up of 6-12 months after the start of treatment, and relapse to smoking is known to occur beyond this period, it is important to evaluate whether the net benefit of NRT in naturalistic settings can be maintained long-term.

Employing a survey research call centre, trained interviewers will contact participants in the original randomized controlled trial, 5 years post-enrollment. A total of 924 subjects will be eligible to be contacted, however intent-to-treat analyses will evaluate outcomes based on all 1000 participants randomized to condition in the original trial. In this 5-year follow-up survey, interviewers will first assess participants' smoking status, the number of cigarettes smoked per day and their level of nicotine dependence. Participants reporting not currently smoking will be asked whether they have smoked tobacco, even a puff, in the last 30 days (primary outcome measure: abstinence using 30 day point prevalence), past 6 months (secondary outcome measure: prolonged 6-month abstinence), and since the last follow-up survey (secondary outcome measure: > 4 year continuous abstinence). Interviewers will be blind to experimental condition at the time the primary outcome measure will be assessed. The survey component of the proposed study will be conducted over a 2 year period to coincide with the duration of subject recruitment in the original trial. The primary hypothesis is that subjects who received nicotine patches at baseline will display significantly higher quit rates at the 5-year follow-up as compared to subjects who did not receive nicotine patches at baseline.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 1000
• Est. completion date: August 22, 2019
• Est. primary completion date: August 22, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• 18 years of age and older

• Current daily smokers who smoke 10 or more cigarettes per day

• Interested in being involved in a smoking study

• Willing to be interviewed at baseline, 8 weeks and 6 months after

• Willing to provide a saliva sample for cotinine analysis at each time point

• Interest in using nicotine patch to quit smoking

• Intent to use nicotine patch within one week of receiving it

• Willing to have nicotine patch sent to their home

Exclusion Criteria:

• Have a medical condition that would would make participation medically hazardous as determined by the list of contraindications for NRT outlined in the CPS and the NRT package insert

• Pregnant, intending on becoming pregnant, or nursing

Related Conditions & MeSH terms

• Smoking Cessation

Intervention

Drug:
• Nicotine patch
mailed 5-week course of Habitrol® transdermal nicotine patches

Locations

Country	Name	City	State
Canada	Centre for Addiction and Mental Health	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health	Canadian Cancer Society Research Institute (CCSRI)

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Smoking Cessation	self-reported 30-day point prevalence abstinence	5-years post intervention
Secondary	Prolonged Abstinence	self-reported prolonged 6-month abstinence	5 years post intervention
Secondary	Continuous Abstinence	self-reported continuous > 4 years abstinence	5 years post intervention

External Links

•   Information about research at the Centre for Addiction and Mental Health, Canada's largest mental health and addiction teaching hospital, fully affiliated with the University of Toronto, and a PAHO/WHO Collaborating Centre